Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

My Dad the Renaissance Man.

Pruitt SK.

J Trauma Acute Care Surg. 2019 Jul 11. doi: 10.1097/TA.0000000000002422. [Epub ahead of print] No abstract available.

PMID:
31318763
2.

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.

Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A.

J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.

PMID:
30943124
3.

Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers.

Singh U, Cui Y, Dimaano N, Mehta S, Pruitt SK, Yearley J, Laterza OF, Juco JW, Dogdas B.

Biotech Histochem. 2018;93(6):411-423. doi: 10.1080/10520295.2018.1445290. Epub 2018 Jun 4.

PMID:
29863904
4.

Impact of delayed lymphoscintigraphy for sentinel lymphnode biopsy for breast cancer.

Wang H, Heck K, Pruitt SK, Wong TZ, Scheri RP, Georgiade GS, Ichite I, Hwang ES.

J Surg Oncol. 2015 Jun;111(8):931-4. doi: 10.1002/jso.23915. Epub 2015 May 7.

PMID:
25953313
5.

High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes.

Nair SK, Tomaras GD, Sales AP, Boczkowski D, Chan C, Plonk K, Cai Y, Dannull J, Kepler TB, Pruitt SK, Weinhold KJ.

Sci Rep. 2014 Apr 23;4:4632. doi: 10.1038/srep04632.

6.

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, Selim MA, Mitchell DA, Sampson J, Tyler DS, Pruitt SK.

J Clin Invest. 2013 Jul;123(7):3135-45. doi: 10.1172/JCI67544. Epub 2013 Jun 24.

7.

Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.

Tan C, Dannull J, Nair SK, Ding E, Tyler DS, Pruitt SK, Lee WT.

J Surg Res. 2013 Dec;185(2):904-11. doi: 10.1016/j.jss.2013.06.045. Epub 2013 Jul 17.

PMID:
23891424
8.

Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.

Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT.

J Transl Med. 2013 Jun 17;11:148. doi: 10.1186/1479-5876-11-148.

9.

Melanoma, version 2.2013: featured updates to the NCCN guidelines.

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2013 Apr 1;11(4):395-407.

PMID:
23584343
10.

Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Salama AK, de Rosa N, Scheri RP, Pruitt SK, Herndon JE 2nd, Marcello J, Tyler DS, Abernethy AP.

PLoS One. 2013;8(3):e57665. doi: 10.1371/journal.pone.0057665. Epub 2013 Mar 13.

11.

Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.

Shetty G, Beasley GM, Sparks S, Barfield M, Masoud M, Mosca PJ, Pruitt SK, Salama AK, Chan C, Tyler DS, Weinhold KJ.

Ann Surg Oncol. 2013 Apr;20(4):1128-35. doi: 10.1245/s10434-012-2785-5. Epub 2013 Mar 2.

12.

The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost.

Salama AK, Rosa Nd, Scheri RP, Herndon JE, Tyler DS, Marcello J, Pruitt SK, Abernethy AP.

Cancer Invest. 2012 Nov;30(9):637-41. doi: 10.3109/07357907.2012.726387. Epub 2012 Sep 28.

PMID:
23020583
13.

Melanoma.

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Mar;10(3):366-400. No abstract available.

PMID:
22393197
14.

Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function.

Dannull J, Schneider T, Lee WT, de Rosa N, Tyler DS, Pruitt SK.

Blood. 2012 Mar 29;119(13):3113-22. doi: 10.1182/blood-2011-10-385930. Epub 2012 Feb 8.

15.

Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.

Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S.

Eur J Immunol. 2011 Dec;41(12):3553-63. doi: 10.1002/eji.201141383. Epub 2011 Oct 26.

16.

Sentinel node biopsy for head and neck melanoma: a systematic review.

de Rosa N, Lyman GH, Silbermins D, Valsecchi ME, Pruitt SK, Tyler DM, Lee WT.

Otolaryngol Head Neck Surg. 2011 Sep;145(3):375-82. doi: 10.1177/0194599811408554. Epub 2011 May 3. Review.

PMID:
21540313
17.

Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Peterson B, Seigler H, Pruitt SK, Tyler DS.

J Am Coll Surg. 2011 Aug;213(2):306-16. doi: 10.1016/j.jamcollsurg.2011.03.013. Epub 2011 Apr 13. Erratum in: J Am Coll Surg. 2012 Feb;214(2):245.

18.

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, Padussis J, Pruitt SK, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2010 Jul;9(7):2090-101. doi: 10.1158/1535-7163.MCT-10-0073. Epub 2010 Jun 22.

19.

Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.

Toshimitsu H, Yoshimoto Y, Augustine CK, Padussis JC, Yoo JS, Angelica Selim M, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS.

Ann Surg Oncol. 2010 Aug;17(8):2247-54. doi: 10.1245/s10434-010-0971-x. Epub 2010 Feb 24.

PMID:
20182810
20.

Pediatric melanoma: a single-institution experience of 150 patients.

Aldrink JH, Selim MA, Diesen DL, Johnson J, Pruitt SK, Tyler DS, Seigler HF.

J Pediatr Surg. 2009 Aug;44(8):1514-21. doi: 10.1016/j.jpedsurg.2008.12.003.

PMID:
19635298
21.

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, Zager JS, Hochwald SN, Grobmyer SR, Delman KA, Andtbacka RH, Noyes RD, Kane JM, Seigler H, Pruitt SK, Ross MI, Tyler DS.

J Am Coll Surg. 2009 May;208(5):706-15; discussion 715-7. doi: 10.1016/j.jamcollsurg.2008.12.019. Epub 2009 Mar 26.

PMID:
19476821
22.

Melanoma.

Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK; NCCN Melanoma Panel.

J Natl Compr Canc Netw. 2009 Mar;7(3):250-75. No abstract available.

PMID:
19401060
23.

Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.

Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Sanders G, Cheng TY, Pruitt SK, Seigler H, Tyler DS.

Ann Surg Oncol. 2008 Aug;15(8):2195-205. doi: 10.1245/s10434-008-9988-9. Epub 2008 Jun 5.

PMID:
18528730
24.

Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity.

Dannull J, Lesher DT, Holzknecht R, Qi W, Hanna G, Seigler H, Tyler DS, Pruitt SK.

Blood. 2007 Dec 15;110(13):4341-50. Epub 2007 Sep 12.

25.

Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.

Yoshimoto Y, Augustine CK, Yoo JS, Zipfel PA, Selim MA, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2007 May;6(5):1492-500. Epub 2007 May 4.

26.

Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.

Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK.

Ann Surg Oncol. 2006 Dec;13(12):1645-54.

PMID:
16957968
27.

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.

Ueno T, Ko SH, Grubbs E, Yoshimoto Y, Augustine C, Abdel-Wahab Z, Cheng TY, Abdel-Wahab OI, Pruitt SK, Friedman HS, Tyler DS.

Mol Cancer Ther. 2006 Mar;5(3):732-8.

28.

Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.

Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z, Chu E, Pruitt SK, Friedman HS, Dewhirst MW, Tyler DS.

Clin Cancer Res. 2006 Jan 1;12(1):289-97.

29.

Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.

Abdel-Wahab Z, Cisco R, Dannull J, Ueno T, Abdel-Wahab O, Kalady MF, Onaitis MW, Tyler DS, Pruitt SK.

J Surg Res. 2005 Apr;124(2):264-73.

PMID:
15820257
30.

Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.

Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS.

Am J Surg. 2004 Nov;188(5):532-7.

PMID:
15546565
31.

The role of hyperthermia in regional alkylating agent chemotherapy.

Abdel-Wahab OI, Grubbs E, Viglianti BL, Cheng TY, Ueno T, Ko S, Rabbani Z, Curtis S, Pruitt SK, Dewhirst MW, Tyler DS.

Clin Cancer Res. 2004 Sep 1;10(17):5919-29.

32.

In-transit melanoma: the role of alkylating-agent resistance in regional therapy.

Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, Colvin OM, Friedman HS, Tyler DS.

J Am Coll Surg. 2004 Sep;199(3):419-27.

PMID:
15325612
33.

Modulation of resistance to regional chemotherapy in the extremity melanoma model.

Grubbs EG, Ueno T, Abdel-Wahab O, Cheng TY, Pruitt SK, Michael Colvin O, Friedman HS, Tyler DS.

Surgery. 2004 Aug;136(2):210-8.

PMID:
15300182
34.

Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4.

Cisco RM, Abdel-Wahab Z, Dannull J, Nair S, Tyler DS, Gilboa E, Vieweg J, Daaka Y, Pruitt SK.

J Immunol. 2004 Jun 1;172(11):7162-8.

35.

Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells.

Kalady MF, Onaitis MW, Emani S, Abdul-Wahab Z, Pruitt SK, Tyler DS.

J Gastrointest Surg. 2004 Feb;8(2):175-81; discussion 181-2.

PMID:
15036193
36.

Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.

Kalady MF, Onaitis MW, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK.

J Surg Res. 2004 Jan;116(1):24-31.

PMID:
14732346
37.

Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.

Abdel-Wahab Z, Kalady MF, Emani S, Onaitis MW, Abdel-Wahab OI, Cisco R, Wheless L, Cheng TY, Tyler DS, Pruitt SK.

Cell Immunol. 2003 Aug;224(2):86-97.

PMID:
14609574
38.

CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.

Onaitis MW, Kalady MF, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK.

Surgery. 2003 Aug;134(2):300-5.

PMID:
12947333
39.

Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.

Kalady MF, Onaitis MW, Padilla KM, Emani S, Tyler DS, Pruitt SK.

J Surg Res. 2002 Jun 1;105(1):17-24.

PMID:
12069496
40.

Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.

Bartlett JA, Miralles GD, Sevin AD, Silberman M, Pruitt SK, Ottinger J, Gryszowska V, Fiscus SA, Bucy RP; ACTG 380 Study Team.

AIDS Res Hum Retroviruses. 2002 May 20;18(8):535-43.

PMID:
12036483
41.

Multimodal therapy for stage IV adult Wilms tumor.

Raj GV, Pruitt SK, Lilly S, Madden JT, Price DT.

J Urol. 2001 Apr;165(4):1202. No abstract available.

PMID:
11257672
42.

Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.

Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J.

J Immunol. 2001 Mar 1;166(5):2953-60.

43.

Timing of sentinel lymph node mapping after lymphoscintigraphy.

White DC, Schuler FR, Pruitt SK, Culhane DK, Seigler HF, Coleman RE, Tyler D.

Surgery. 1999 Aug;126(2):156-61.

PMID:
10455878
44.
45.

Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts.

Pruitt SK, Bollinger RR, Collins BH, Marsh HC Jr, Levin JL, Rudolph AR, Baldwin WM 3rd, Sanfilippo F.

Transplantation. 1997 Mar 27;63(6):900-2.

PMID:
9089232
46.

Overcoming rejection in pig-to-primate cardiac xenotransplantation.

Davis EA, Jakobs F, Pruitt SK, Greene PS, Qian Z, Lam TT, Tseng E, Levin JL, Baldwin WM 3rd, Sanfilippo F.

Transplant Proc. 1997 Feb-Mar;29(1-2):938-9. No abstract available.

PMID:
9123595
47.

Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts.

Davis EA, Pruitt SK, Greene PS, Ibrahim S, Lam TT, Levin JL, Baldwin WM 3rd, Sanfilippo F.

Transplantation. 1996 Oct 15;62(7):1018-23.

PMID:
8878398
48.

Continuous complement (C) inhibition using soluble C receptor type 1 (sCR1): effect on hyperacute rejection (HAR) of pig-to-primate cardiac xenografts.

Pruitt Sk, Bollinger RR, Collins BH, Marsh HC, Levin JL, Rudolph AR, Baldwin WM 3rd, Sanfilippo F.

Transplant Proc. 1996 Apr;28(2):756. No abstract available.

PMID:
8623382
49.

The role of C3a and C5a in hyperacute rejection of guinea pig-to-rat cardiac xenografts.

Pruitt SK, Baldwin WM 3rd, Sanfilippo F.

Transplant Proc. 1996 Apr;28(2):596. No abstract available.

PMID:
8623292
50.

Supplemental Content

Loading ...
Support Center